After-Hours Stock Movers 07/19: (AMRX) (CCK) (IBM) Higher; (ARDX) (RCUS) (PPG) Lower (more...)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Futures extend losses after economic data
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil steady as US demand concerns balance Middle East conflict risks
- Yen at multi-decade lows, dollar drops before US data
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Crude Inventory Declined 6.4 Million Barrels Last Week
- Meta Platforms, IBM, Caterpillar fall premarket; American Airlines, Chipotle rise
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
Ardelyx's (ARDX) Shares Plunge as Tenapanor's Deficiencies Identified by FDA 'Take Approval Off the Table'
July 20, 2021 9:57 AM EDTOn July 19th, 2021, Ardelyx, Inc (NASDAQ: ARDX) disclosed a letter from the US Food and Drug Administration (FDA) relating to its New Drug application for Tenapanor the companys drug candidate for the control of serum phosphorus in adult patients with chronic kidney disease (CKD).
The agency notified the company of identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time, as well as denied a follow-up meeting request by ARDX.
The FDA move took the market by surprise, sending the companys... More
